Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

  • ID: 3783280
  • Drug Pipelines
  • 138 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • ArQule, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Merck KGaA
  • Principia Biopharma Inc.
  • MORE
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

‘Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016’, provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • ArQule, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Merck KGaA
  • Principia Biopharma Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview

Therapeutics Development

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Stage of Development

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Therapy Area

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Indication

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Companies

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Universities/Institutes

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc.

Advinus Therapeutics Ltd

ArQule, Inc.

BeiGene, Ltd.

Bristol-Myers Squibb Company

Celgene Corporation

CrystalGenomics, Inc.

Genentech, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

LSK BioPartners, Inc.

Merck KGaA

Ono Pharmaceutical Co., Ltd.

Pharmacyclics, Inc.

Principia Biopharma Inc.

Redx Pharma Plc

Simcere Pharmaceutical Group

Sunesis Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Drug Profiles

acalabrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARQ-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-3111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-026806 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-036806 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit BTK for Undisclosed Indications - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBI-1266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBI-1367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCI-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCI-1684 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-71224 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-2951 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7583 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4059 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLS-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNQ-154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNQ-849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BTK for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BTK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BTK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNS-062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

spebrutinib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Dormant Projects

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Discontinued Products

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Featured News & Press Releases

Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting

Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund

May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia

May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead

May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016

May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting

May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia

May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients

Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients

Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients

Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia

Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111

Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia

Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AbbVie Inc., H1 2016

Pipeline by Advinus Therapeutics Ltd, H1 2016

Pipeline by ArQule, Inc., H1 2016

Pipeline by BeiGene, Ltd., H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Celgene Corporation, H1 2016

Pipeline by CrystalGenomics, Inc., H1 2016

Pipeline by Genentech, Inc., H1 2016

Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Pipeline by LSK BioPartners, Inc., H1 2016

Pipeline by Merck KGaA, H1 2016

Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Pipeline by Pharmacyclics, Inc., H1 2016

Pipeline by Principia Biopharma Inc., H1 2016

Pipeline by Redx Pharma Plc, H1 2016

Pipeline by Simcere Pharmaceutical Group, H1 2016

Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016

Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • ArQule, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Merck KGaA
  • Principia Biopharma Inc.
  • MORE
According to our recently published report 'Tyrosine-Protein Kinase BTK – Pipeline Review, H1'; Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Bruton's tyrosine kinase also known as tyrosine-protein kinase BTK is an enzyme encoded by the BTK gene. BTK is a kinase that plays a crucial role in B-cell development. BTK plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and is crucial to the activation of host defense. it is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation.

The report 'Tyrosine-Protein Kinase BTK – Pipeline Review, H1' outlays comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7, 15 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
AbbVie Inc.
Advinus Therapeutics Ltd
ArQule, Inc.
BeiGene, Ltd.
Bristol-Myers Squibb Company
Celgene Corporation
CrystalGenomics, Inc.
Genentech, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
LSK BioPartners, Inc.
Merck KGaA
Ono Pharmaceutical Co., Ltd.
Pharmacyclics, Inc.
Principia Biopharma Inc.
Redx Pharma Plc
Simcere Pharmaceutical Group
Sunesis Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll